Used in clinical research for the treatment of various B-cell malignancies, including relapsed or refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. It functions as a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), a key signaling molecule involved in B-cell proliferation, survival, and migration. By targeting this pathway, it helps suppress abnormal B-cell growth and promotes apoptosis in malignant cells. Currently under investigation in phase 1 and 2 trials to evaluate safety, efficacy, and optimal dosing in hematologic cancers.